

BIOMELBOURNE NETWORK

# *Connecting Women Lunch*

16 MAY 2025

## PREMIER SPONSOR



CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit [CSL.com/Vita](https://www.csl.com/Vita) and follow us on [Twitter.com/CSL](https://twitter.com/CSL).

For more information about CSL, visit [CSL.com](https://www.csl.com).

## MAJOR SPONSORS



**CITY OF MELBOURNE**

Melbourne City Council is the local government body responsible for the municipality of Melbourne. Our elected Council entails of a lord mayor, deputy lord mayor and nine councillors.

The administration involves a chief executive officer, executive leadership team and about 1770 staff. The Council is the decision-making body that sets the strategic direction and policy of the municipality. It delivers the four-year Council Plan, which sets out what the Council will achieve during its four-year term to further the community vision, and the Annual Plan and Budget, which describes the Council's key objectives and activities for each 12-month period.



Phillips Ormonde Fitzpatrick are the IP protection people who are great to work with, transforming creativity and innovation into commercial edge. We have been in operation for over 130 years and are a market leader in the IP profession, managing our client's IP in Australia and internationally from inception to commercialisation, enforcement, litigation, and defence.

Our professionals work with innovators at the cutting edge of advancements in science and technology with bringing products and services to market. We embrace diversity and proudly recognise women in leadership and are delighted to be an inaugural sponsor of the BioMelbourne Network Women's luncheon.

# R&DIUM CAPITAL

Radium Capital is Australia's market leader in R&D financing. We were formed by entrepreneurs for entrepreneurs. That's why we don't think like a bank!

We believe businesses with R&D should have access to capital when they need it. So, we created Radium Advances to provide quick, easy and early access to up to 80% of your expected R&D tax incentive refund. Radium Advances are available as a one-off cash injection or can be used strategically multiple times throughout the year to smooth cash flow. The more you use Radium Advances the more your R&D benefits. Under a quarterly model, for the same expenditure, you can:

- boost your R&D spend by 50% or reduce your outlay by 33%.
- reinvest up to 150% of R&D expenditure back into R&D.

Since launching in 2017, Radium Capital has provided **\$900m** of funding to Australian innovation businesses. Find out how innovators across Australia are using non-dilutive R&D financing to accelerate growth, attract other sources of funding and smooth cash flow at [radiumcapital.com.au](http://radiumcapital.com.au)

## SIGNATURE SPONSORS



**Avatar Brokers** has been a leading independent insurance specialist in Australia for over 20 years. Avatar caters to innovative enterprises with expert risk management solutions. Our clients seek proactive partners who understand their unique products and the evolving business landscape. That's where Avatar's specialist expertise comes into play.

As the only endorsed broker for key life science bodies, we bring expertise to the industry. Seventy per cent of our clients come from technology, life sciences, green energy, and related sectors, reflecting our focus in serving dynamic businesses. We are proud to be the endorsed broker for **AusBiotech**, **BioMelbourne Network**, **Life Sciences Queensland**, and the **Affiliated Partner of TechAssure**. Our reputation underscores our commitment to excellence and deep industry insight, earning us recognition as the **Accredited Industry Expert for Victorian Leaders**.

Managing risk can be complex, so we make it simple. Our specialised team understands the challenges life science companies face, streamlining the risk transfer process so clients can focus on what matters most—their growth and success.



Melbourne Convention Bureau (MCB) is Victoria's leading full-service agency in acquiring and delivering international and national conferences and corporate business events. MCB has representation in six countries, including the United Kingdom, United States, China, Malaysia and India. MCB are a part of Visit Victoria and are supported by the State Government of Victoria and over 150 industry partners. MCB works closely with academia, industry, and government to secure high-impact conferences and business events for Melbourne and Victoria.

Business events deliver significant economic, educational and social outcomes. They foster collaboration, knowledge transfer, professional development and global profiling. If you are interested in hosting a conference in Melbourne, read more about Conference Leadership [here](#) and contact our team members for an explorative discussion.

## SUPPORTING SPONSORS



mexec is an Executive Search Recruitment firm that that assists companies in the biotechnology, health and innovation sectors to build their leadership teams.

We also provide support to individuals seeking to transition to new roles.

Reach out to us today on [careers@mexec.com](mailto:careers@mexec.com) or visit our website at [www.mexec.com](http://www.mexec.com)



Cell Therapies has been the leading cell and gene therapy manufacturing organisation in Australia for over 20 years. Cell Therapies is at the forefront of bringing approved therapies to Australian patients and working with Australian researchers and biotech companies to develop home-grown cell and gene therapy products. Our expertise spans across the product development pipeline from first-in-human, early to late phase clinical trials, through to commercial supply for patients across Australia and the Asia Pacific region.

Cell Therapies is Australia's only TGA-licensed biomedical manufacturing facility where CAR T-cells and other "living" cell-based therapies can be produced at commercial volumes. The facility supports manufacture of both autologous and allogeneic products and includes large-scale high-throughput GMP manufacturing suites for late-phase and commercial supply with a production capacity of up to 2,000 patient doses per year. Co-located with the Peter MacCallum Cancer Centre in the Parkville Biomedical Precinct, Melbourne, Cell Therapies meets many international regulatory agency requirements, including those of the Australian TGA, the US FDA, Japan's PMDA, and Europe's EMA.



Crux Biolabs is an Australian bioanalytical laboratory specialising in PBMC processing, pharmacodynamics (biomarker, flow cytometry and ADA) and pharmacokinetics (large and small molecule) for clinical research.

Our expert scientists can customise and validate a wide range of biomarker and cell assays in our ISO 17025- accredited lab in Melbourne, Australia. We also offer PBMC processing in Sydney with our dedicated satellite laboratory.

We understand that each study is unique. That's why we take pride in becoming an extension of your team to deliver the best outcome for your clinical studies. Crux Biolabs - where science leads.



Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. We are headquartered in Melbourne, with operations in the U.S., Brazil, Canada, Europe, and Japan. Our mission is to be the global leader in our field by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as 'theranostics'.

We have an extensive pipeline of theranostic radiopharmaceutical candidates, with a focus on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and hematologic oncology bone marrow conditioning. Our theranostic approach is intended to use imaging and therapy together to 'see and treat' cancer and rare diseases, to both better inform treatment decisions and deliver personalised therapy for patients.

Our lead imaging product – Illuccix® for prostate cancer imaging (also known as <sup>68</sup>Ga-PSMA-11) is commercially available in the U.S., Australia, Brazil, Canada, New Zealand, the United Kingdom and multiple European Economic Area member states. Our next-generation <sup>68</sup>Ga-PSMA-11 prostate cancer imaging product, Gozellix® has been approved by the U.S. FDA.

Visit <https://telixpharma.com/> for more or follow us on LinkedIn.



For more than 50 years, La Trobe University has been transforming people and societies. The University works collaboratively across disciplines and with partners to develop fresh ways of thinking and conducting research – constantly seeking new ways to engage with and better serve its partners and communities, to build relationships and develop solutions for the issues facing society. Along with holding its top 300 ranking in Times Higher Education's World University Rankings 2025, La Trobe earned the prestigious 'Most Improved – Oceania Award' in the QS World University Rankings 2025, rising 183 places over the past five years to claim its new spot at 217 of the 1,500 universities evaluated. Read more about La Trobe [here](#).